Why is Cohance Life falling/rising?

As of 23-Sep, Cohance Lifesciences Ltd is experiencing a decline in its stock price, currently at Rs 900.10, reflecting a decrease of -1.65 (-0.18%). The stock has been underperforming, having fallen consecutively for the last five days, resulting in a total decline of -9.04% over the past week. It is also trading close to its 52-week low, just 4.8% above Rs 856.9. The stock's performance has been weak, with a year-to-date return of -20.58% compared to a positive return of +5.07% for the benchmark. Factors contributing to this decline include a significant drop in investor participation, with delivery volume falling by -94.4% against the five-day average, and the stock trading below all key moving averages. Additionally, the company has shown poor long-term growth, with operating profit growth at only 2.95% over the last five years, and a substantial increase in pledged promoter shares, which adds downward pressure in a falling market.
In the broader market context, while the Sensex has only declined by -0.34% over the past week, Cohance Lifesciences Ltd's performance has been significantly worse, indicating a lack of investor confidence relative to the market. The stock's negative return of -27.99% over the past year starkly contrasts with the benchmark's decline of -3.33%, highlighting its underperformance. Despite a high return on equity of 24.14% and a low debt-to-equity ratio, the company's valuation appears expensive compared to peers, which may deter potential investors. The combination of these stock-specific factors and the broader market context suggests that the stock's recent movement is primarily influenced by internal challenges and a lack of market support.